Document:

Repurchase Agreement dated December 20, 2007

 Exhibit 10.10 
 REPURCHASE AGREEMENT 
 This Repurchase Agreement (the
“Agreement”), dated as of December 20, 2007, is by and between CHINA NUOKANG BIO-PHARMACEUTICAL PTY, a company incorporated and existing under the laws of the Cayman Islands (the “Purchaser” or
“Company”), and Anglo China Bio-technology Investment Holdings Limited, a company incorporated and existing under the laws of the British Virgin Islands (the “Seller”). The Purchaser and the Seller are sometimes
referred to collectively herein as the “Parties.” 
 W I T N E S
S E T H: 
 WHEREAS, the Seller is the ultimate legal and beneficial owner of 4,552,352 Ordinary
Shares (the “Shares”) of the Company; and 
 WHEREAS, the Purchaser desires to purchase from the Seller, and
the Seller desires to sell to the Purchaser, all and not less than all of the Shares. 
 NOW, THEREFORE, in consideration of the
foregoing and the mutual representations, warranties, covenants and agreements herein contained, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties agree as follows: 

ARTICLE I 
 PURCHASE AND SALE 
 Section 1.1 Purchase of Shares. Subject to the terms and conditions of
this Agreement, the Seller hereby sells, conveys, assigns and transfers to the Purchaser, and the Purchaser hereby purchases from the Seller, the Shares, free and clear of any pledge, mortgage, security interest, encumbrance, lien, charge,
assessment or restriction of any kind or nature. 
 Section 1.2 Purchase Price. The consideration payable by
the Purchaser to the Seller shall be US$ US$0.6590 per Share. The total consideration payable by the Purchaser to the Seller is US$ 2,999,999.968 (the “Purchase Price”). 
 Section 1.3 Closing. The closing (the “Closing”) of the purchase and sale of the Shares shall be held at the
Shanghai offices of Latham & Watkins LLP, at 11:00 am on December 20, 2007 or any other date and time that is agreed upon by the Seller and the Purchaser (the date on which the closing occurs, the “Closing Date”). At
the Closing, (a) the Seller shall deliver or cause to be delivered to the Purchaser certificates representing the Seller’s Shares, registered in the name of the Purchaser (or its nominee), or duly endorsed in blank or accompanied by stock
powers duly endorsed in blank in proper form for transfer, with appropriate transfer stamps, if any, affixed, and any and all other documents as may be reasonably requested by Purchaser or required by the laws of the Cayman Islands to effect the
sale and transfer of the Shares, and (b) the Purchaser shall deliver the Purchase Price by wire transfer in immediately available funds to the Seller’s bank account as follows: 
  

			
	Bank:	  	The Hongkong and Shanghai Banking Corporation Limited
	Address:	  	Hong Kong Office, HSBC Main Building,
		  	1 Queen’s Road Central, Central, Hong Kong
	Account Name:	  	Anglo China Bio-technology Investment Holdings Limited
	Account No.:	  	808-216691-838
	Swift Code:	  	HSBCHKHHHKH

  

 1 

 ARTICLE II 
 REPRESENTATIONS AND WARRANTIES 
 Section 2.1
Representations and Warranties of the Sellers. The Seller hereby represents and warrants to the Purchaser, as of the date hereof and as of the Closing Date, as follows: 
 (a) Capacity; Due Authorization. The Seller has the capacity, and due authorization, if applicable, to execute and deliver this
Agreement and to perform its obligations hereunder. This Agreement constitutes the valid and legally binding obligations of the Seller, enforceable in accordance with its respective terms and conditions, except (i) as limited by applicable
bankruptcy, insolvency, reorganization, moratorium, and other laws of general application affecting enforcement of creditors’ rights generally, and (ii) as limited by laws relating to the availability of specific performance, injunctive
relief, or other equitable remedies. 
 (b) Noncontravention. Neither the execution and the delivery of this Agreement,
nor the consummation of the transactions contemplated hereby, will (x) violate any constitution, statute, regulation, rule, injunction, judgment, order, decree, ruling, charge, or other restriction of any government, governmental entity or
court to which the Seller is subject, or (y) violate any organizational documents of the Seller including but not limited to the Memorandum and Articles of Association, or (z) conflict with, result in a breach of, constitute a default
under, result in the acceleration of or creation of an encumbrance under, create in any party the right to accelerate, terminate, modify, or cancel, or require any notice under, any agreement, contract, lease, license, permit, instrument, or other
arrangement to which the Seller is a party or by which it is bound or to which any of its assets are subject. There is no action, suit or proceeding, pending or threatened against the Seller that questions the validity of this Agreement or the right
of the Seller to enter into this Agreement or to consummate the transactions contemplated hereby or thereby. There is no action, suit or proceeding pending or, to the knowledge, after due inquiry, of the Seller, threatened against such Seller, nor
is there any investigation pending against such Seller, that questions the validity of this Agreement or the right of such Seller to enter into this Agreement or to consummate the transactions contemplated hereby or thereby. 
 (c) Consents and Approvals. Neither the execution and delivery by the Seller of this Agreement, nor the consummation by the Seller of
any of the transactions contemplated hereby, nor the performance by the Seller of this Agreement in accordance with its terms requires the consent, approval, order or authorization of, or filing or registration with, or the giving notice to, any
governmental or public body or authority or any third party, except such as have been obtained, made or given. 
  

 2 

 (d) Title to Shares. The Seller is the legal and beneficial owner of the Shares. The
Seller’s Shares have been duly authorized and validly issued, are fully paid and non-assessable, are owned by such Seller, and are so owned by such Seller, free and clear of any encumbrances. The Shares are not subject to any voting trust or
other agreement relating to the voting thereof, or restricting in any way the sale or transfer thereof. Upon delivery by such Seller of the certificates representing the Shares pursuant to this Agreement and the consummation of the transactions
contemplated hereby, the Purchaser will acquire good and valid title to the Shares, free and clear of any pledge, mortgage, security interest, encumbrances, lien, charge, assessment or restitution of any kind or nature. 
 (e) No Broker. The Seller has not employed any broker, finder, advisor or intermediary in connection with the transactions
contemplated by this Agreement that would be entitled to a broker’s fee, finder’s or similar fee or commission in connection therewith or upon the consummation thereof. 
 (f) No Reliance. In making its decision to sell the Shares pursuant to this Agreement, the Seller has not requested, or been
furnished with, or relied on any information concerning the Company or the Shares provided to such Seller by the Purchaser. 
 Section 2.2 Representations and Warranties of the Purchaser. The Purchaser hereby represents and warrants to the Seller, as of the date hereof and as of the Closing Date, as follows: 
 (a) Capacity, Due Authorization. The Purchaser has full power and authority to enter into, execute and deliver this Agreement and
each agreement, certificate, document and instrument to be executed and delivered by the Purchaser pursuant to this Agreement and to perform its obligations hereunder. The execution and delivery by the Purchaser of this Agreement and the performance
by the Purchaser of its obligations hereunder have been duly authorized by all requisite actions on its part. 
 (b) Valid
Agreement. This Agreement has been duly executed and delivered by the Purchaser and constitutes the legal, valid and binding obligation of the Purchaser, enforceable against it in accordance with its terms, except (i) as limited by
applicable bankruptcy, insolvency, reorganization, moratorium, and other laws of general application affecting enforcement of creditors’ rights generally, and (ii) as limited by laws relating to the availability of specific performance,
injunctive relief, or other equitable remedies. 
 (c) Consents and Approvals. Neither the execution and delivery by the
Purchaser of this Agreement nor the consummation by it of any of the transactions contemplated hereby nor the performance by the Purchaser of this Agreement in accordance with its terms requires the consent, approval, order or authorization of, or
registration with, or the giving of notice to, any governmental or public body or authority or any third party, except as have been obtained, made or given. 
  

 3 

 (d) No Conflict. Neither the execution and delivery by the Purchaser of this
Agreement, nor the consummation by it of any of the transactions contemplated hereby, nor compliance by the Purchaser with any of the terms and conditions hereof will contravene any existing agreement, federal, state, county or local law, rule or
regulation or any judgment, decree or order applicable to, or binding upon, the Purchaser. 
 (e) No Broker. The
Purchaser has not employed any broker, finder, advisor or intermediary in connection with the transactions contemplated by this Agreement that would be entitled to a broker’s fee, finder’s or similar fee or commission in connection
therewith or upon the consummation thereof. 
 (f) No Reliance. In making its decision to purchase the Shares pursuant to
this Agreement, the Purchaser has not requested, or been furnished with, or relied on any information concerning the Shares provided to the Purchaser by the Seller. 
 ARTICLE III 
 INDEMNIFICATION 
 Section 3.1 Indemnification of the Sellers. The Purchaser shall defend and promptly indemnify and hold harmless the
Seller and its officers, directors, partners, attorneys and representatives (collectively “Seller Indemnified Parties”) from, against, for, and in respect of and pay any and all Losses (as defined in Section 3.3) suffered,
sustained, incurred or required to be paid by such Seller arising out of or resulting from: 
 (a) any material breach of any
representation, warranty, covenant or agreement of the Purchaser contained in this Agreement; and 
 (b) the successful
enforcement by any Seller Indemnified Party of any of its rights under this Section 3.1. 
 Section 3.2
Indemnification of the Purchaser. The Seller shall, jointly and severally, defend and promptly, indemnify, and hold harmless, severally and not jointly, the Purchaser, and its officers, directors, partners, affiliates, subsidiaries,
attorneys and representatives (collectively “Purchaser Indemnified Parties”) from, against, for and in respect of and pay any and all Losses suffered, sustained, incurred or required to be paid by any such party arising out of or
resulting from: 
 (a) any material breach of any representation, warranty, covenant or agreement of each of the Sellers
contained in this Agreement; and 
 (b) the successful enforcement by any Purchaser Indemnified Party of any of its rights under
this Section 3.2. 
 Section 3.3 Definition of Losses. For purposes of this Section 3,
“Losses” shall mean all damages, awards, judgments, assessments, fines, penalties, charges, costs and expenses and other payments (excluding punitive or consequential damages) however suffered or characterized, all interest thereon,
all costs and expenses of investigating any claim, lawsuit or arbitration and any appeal therefrom, all reasonable attorneys’, accountants’, investment bankers’, and expert witness’ fees incurred in connection therewith, whether
or not such claim, lawsuit or arbitration is ultimately defeated and, subject to this Section 3, all amounts paid incident to any compromise or settlement of any such claim, lawsuit or arbitration; provided, however, that any
compromise or settlement shall not be entered into without the consent of the party from whom indemnification is sought (such consent shall not be unreasonably withheld). 
  

 4 

 ARTICLE IV 
 MISCELLANEOUS 
 Section 4.1 Survival of
the Representations and Warranties. All representations and warranties made by any Party shall survive for two years and shall terminate and be without further force or effect on the second anniversary of the date hereof, except as to
(i) any claims thereunder which have been asserted in writing against the Party making such representations and warranties on or prior to such second anniversary, and (ii) each Seller’s representation contained in Section 2.1(d)
hereof. 
 Section 4.2 Termination. This Agreement may be terminated, and the transactions contemplated
hereby may be abandoned at any time prior to Closing, (i) by mutual agreement of the Parties, or (ii) by the written notice of the Seller or the Purchaser to the other in the event that the Closing has not occurred by December 31,
2007. 
 Section 4.3 Governing Law; Arbitration. This Agreement shall be governed and interpreted in
accordance with the laws of the State of New York without giving effect to the conflicts of law principles thereof. In the event the parties are unable to settle a dispute between them regarding this Agreement, such dispute shall be referred to and
finally settled by arbitration at the Hong Kong International Arbitration Centre in accordance with the UNCITRAL Arbitration Rules (“UNCITRAL Rules”) in effect, which rules are deemed to be incorporated by reference into this
subsection (b), subject to the following: (i) the arbitration tribunal shall consist of three arbitrators to be appointed according to the UNCITRAL Rules, and at least one arbitrator is licensed to practice New York law; and (ii) the
language of the arbitration shall be English. The prevailing party shall be entitled to reasonable attorney’s fees, costs and necessary disbursements in addition to any other relief to which such party may be entitled. 
 Section 4.4 Amendment. This Agreement shall not be amended, changed or modified, except by another agreement in writing
executed by the Parties hereto. 
 Section 4.5 Binding Effect. This Agreement shall inure to the benefit of,
and be binding upon, each of the Seller and the Purchaser and their respective heirs, successors and permitted assigns and legal representatives. 
 Section 4.6 Assignment. Neither this Agreement nor any of the rights, duties or obligations hereunder may be assigned by the Seller or the Purchaser without the express written consent
of the other. Any purported assignment in violation of the foregoing sentence shall be null and void. 
  

 5 

 Section 4.7 Notices. All notices and other communications given or made
pursuant to this Agreement shall be in writing and shall be deemed effectively given: (a) upon personal delivery to the party to be notified, (b) when sent by confirmed electronic mail or facsimile if sent during normal business hours of
the recipient, and if not so confirmed, then on the next business day, (c) five (5) days after having been sent by registered or certified mail, return receipt requested, postage prepaid, or (d) one business (1) day after deposit
with an internationally recognized overnight courier, specifying next business day delivery, with written verification of receipt. 
 Any Party may change its address for purposes of this Section 4.7 by giving the other Party hereto written notice of the new address in the manner set forth above. 
 Section 4.8 Entire Agreement. This Agreement constitutes the entire understanding and agreement between the Parties
hereto with respect to the matters covered hereby, and all prior agreements and understandings, oral or in writing, if any, between the Parties with respect to the matters covered hereby are merged and superseded by this Agreement. 
 Section 4.9 Severability. If any provisions of this Agreement shall be adjudicated to be illegal, invalid or
unenforceable in any action or proceeding whether in its entirety or in any portion, then such provision shall be deemed amended, if possible, or deleted, as the case may be, from the Agreement in order to render the remainder of the Agreement and
any provision thereof both valid and enforceable, and all other provisions hereof shall be given effect separately therefrom and shall not be affected thereby. 
 Section 4.10 Fees and Expenses. Except as otherwise provided in this Agreement, each Party will bear its own direct expenses incurred in connection with the negotiation, preparation and
execution of this Agreement. 
 Section 4.11 Headings. The headings of the various articles and sections of
this Agreement are inserted merely for the purpose of convenience and do not expressly or by implication limit, define or extend the specific terms of the section so designated. 
 Section 4.12 Execution in Counterparts. For the convenience of the Parties and to facilitate execution, this Agreement
may be executed in one or more counterparts, each of which shall be deemed to be an original, but all of which together shall constitute but one and the same instrument. 
 [SIGNATURE PAGE FOLLOWS] 
  

 6 

 IN WITNESS WHEREOF, the Parties have caused this Agreement to be executed as of the day and
year first above written. 
  

			
	 CHINA NUOKANG BIO-
 PHARMACEUTICAL PTY

		
	By:	 	 /s/ Xue Baizhong

	Name:	 	Xue Baizhong
	Title:	 	Director
		
	Address:	 	 C/11F, Huaxin International Tower
 No. 219, Qingnian Street

		 	Shenhe District
		 	Shenyang, PRC 110016
	Fax:	 	0086 24 2396 4254
	Email:	 	LNNK_CEO@lnnk.net

  

			
	 Anglo China Bio-Technology Investment
 Holdings Limited

		
	By:	 	 /s/ Xue Baizhong

	Name:	 	Xue Baizhong
	Title:	 	Director
		
	Address:	 	C/11F, Huaxin International Tower
		 	No. 219, Qingnian Street
		 	Shenhe District
		 	Shenyang, PRC 110016
	Fax:	 	0086 24 2396 4254
	Email:	 	LNNK_CEO@lnnk.netEnglish translation of Equity Pledge Agreement dated December 14, 2007

  
 Exhibit 10.11 
 This is an English translation 
 Equity Pledge Agreement 
 This Equity Pledge Agreement (the
“Agreement”) is entered into on December 14, 2007 in Shenyang, China by and between the following parties: 
 Pledgee: Penglai
Nuokang Pharmaceutical Co., Ltd. 
 Address: No.136, Nanguan Road, Penglai City 
 Pledgor: XUE Baizhong 
 PRC Identity Card No.: 220104196509011554 
 Address: 4-3-2, No. 13, Chongshan Middle Road, Huanggu District, Shenyang City 
 WHEREAS, 
  

	1.	XUE Baizhong, the Pledgor, is a citizen of the People’s Republic of China (the “PRC”). The Pledgor owns 100% of the equity interest in Liaoning Nuokang
Medicines Co., Ltd., or Nuokang Medicines. Nuokang Medicines is a high technology company registered in Shenyang of the PRC and carries on the business of wholesaling Chinese formulated medicines, chemical medicines, antibiotics and biochemical
medicines; 

  

	2.	The Pledgee is a wholly foreign-owned company registered in Penglai, the PRC. The Pledgee and Nuokang Medicines, a company owned by the Pledgor, entered into an
Exclusive Technology Support and Management Consulting Service Agreement (the “Service Agreement”) on December 14, 2007. 

  

	3.	The Pledgee, the Pledgor and Nuokang Medicines entered into a Business Operation Agreement (the “Operation Agreement”) on December 14, 2007.

  

	4.	In order to guarantee that the Pledgee can collect the technology consulting service fees from Nuokang Medicines owned by the Pledgor and that the Pledgor and Nuokang
Medicines perform their obligations under the Operation Agreement, the Pledgor hereby pledges all his equity interest in Nuokang Medicines to the Pledgee as a security for: (i) the consulting service fees to be received by the Pledgee under the
Service Agreement; and (ii) the damages caused to the Pledgee by the Pledgor and/or Nuokang Medicines if the Pledgor and/or Nuokang Medicines fail to perform their obligations under the Operation Agreement. 

  
 In order to perform terms under the Service Agreement, the Pledgee and the Pledgor, through negotiations, hereby enter into this Agreement based upon the following terms: 
  

	1.	Definitions 

 Unless otherwise
provided for in this Agreement, the following terms shall have the following meanings: 
  

	 	1.1.	“Pledge” means the entire content of Article 2 hereunder. 

  

	 	1.2.	“Equity Interest” means all the equity interests in Nuokang Medicines legally held by the Pledgor. 

  

	 	1.3.	“Term of Pledge” means the period provided for under Article 3.2. 

  

	 	1.4.	“Service Agreement” means the Exclusive Technology Support and Management Consulting Service Agreement entered into by and between the Pledgee and Nuokang
Medicines, as amended or renewed. 

  

	 	1.5.	“Event of Default” means any event set forth in Article 7 hereunder. 

  

	 	1.6.	“Notice of Default” means the notice of default issued by the Pledgee in accordance with this Agreement. 

  

	2.	Pledge 

  

	 	2.1.	The Pledgor agrees to pledge all his Equity Interest in Nuokang Medicines to the Pledgee as a security for the technology consulting service fee payable to the Pledgee
and damages caused to the Pledgee by the Pledgor and/or Nuokang Medicines if the Pledgor and/or Nuokang Medicines fail to perform their obligations under the Operation Agreement. 

  

	 	2.2.	The pledge under this Agreement refers to the preferential rights enjoyed by the Pledgee in receiving proceeds from auction or sale of the Equity Interest pledged by
the Pledgor to the Pledgee. 

  

	3.	Term of Pledge 

  

	 	3.1.	The term of Pledge 

  

	 	3.1.1.	The Pledge on the Equity Interest under this Agreement shall take into effect as of the date when the Equity Interest under this Agreement is recorded in the register
of shareholders of Nuokang Medicines. The term of the Pledge is the same as the term of the Service Agreement. 

  
  

	 	3.1.2.	During the term of the Pledge, the Pledgee shall be entitled to dispose of or exercise the Pledge in accordance with this Agreement if Nuokang Medicines fails to pay
the technology consulting service fee in accordance with the Service Agreement or the Pledgor and/or Nuokang Medicines cause damages to the Pledgee because of their failure to perform their obligations under the Operation Agreement.

  

	4.	Custody of Pledge Certificate 

  

	 	4.1.	During the term of the Pledge under this Agreement, the Pledgor shall deliver the Equity Interest Investment Certificate of Nuokang Medicines (if any) to the Pledgee
for custody. The Pledgor shall deliver the above Equity Interest Investment Certificate to the Pledgee within a week after the date of this Agreement. 

  

	5.	Representations and Warranties of the Pledgor 

  

	 	5.1.	The Pledgor has fulfilled the obligation of making his capital contribution and is the legal owner of the Equity Interest. 

  

	 	5.2.	Unless otherwise provided for hereunder, to the extent permitted under the PRC laws, the Pledgee shall not be interfered by any other party at any time when exercising
its rights in accordance with this Agreement. 

  

	 	5.3.	Unless otherwise provided for hereunder, to the extent permitted under the PRC laws, the Pledgee shall be entitled to dispose of and assign the Pledge in accordance
with this Agreement. The Pledgor shall unconditionally provide necessary assistance to the Pledgee in exercising its rights. 

  

	 	5.4.	The Pledgor has not created any encumbrance over the Equity Interest in favor of any other person except for the Pledgee. 

  

	6.	Covenant of the Pledgor 

  

	 	6.1.	During the effective term of this Agreement, the Pledgor covenants to the Pledgee that the Pledgor shall perform and, as the shareholder of Nuokang Medicines, shall
procure Nuokang Medicines to perform the following obligations: 

  

	 	6.1.1.	Except for the transfer of Equity Interest by the Pledgor pursuant to the Exclusive Call Option Agreement entered into among the Pledgor, Penglai Nuokang Pharmaceutical
Co., Ltd. and Nuokang Medicines, to Penglai Nuokang Pharmaceutical Co., Ltd. or any person designated by Penglai Nuokang Pharmaceutical Co., Ltd., without prior written consent from the Pledgee, the Pledgor shall not transfer or assign all or part
of the Equity Interest, create or permit the creation of any pledge which may have an adverse effect on the rights or benefits of the Pledgee; 

  
  

	 	6.1.2.	Without prior written consent from the Pledgee, Nuokang Medicines will not, in any form, supplement, change or amend its articles of association, increase or decrease
its registered capital, or change its capital structure in any other ways; 

  

	 	6.1.3.	During the term of the Pledge, without prior written consent from the Pledgee, Nuokang Medicines shall not sell, transfer, mortgage or otherwise dispose of any assets,
interest of business or income above RMB 2,000,000 (inclusive), or create any encumbrance of security interest thereon; 

  

	 	6.1.4.	without the prior written consent of the Pledgee, Nuokang Medicines shall not incur, inherit, guarantee or permit the existence of any debt, except for: (i) the
debt arising from ordinary or daily course of business and not as a result of any borrowings; (ii) the debt having been disclosed to the Pledgee and for which written consent from the Pledgee have been obtained; 

  

	 	6.1.5.	Nuokang Medicines shall not merge or consolidate with any person, or acquire any person or invest in any person without prior written consent from the Pledgee;

  

	 	6.1.6.	Nuokang Medicines shall not enter into any material contract with a value of more than RMB 2,000,000 without prior written consent from the Pledgee;

  

	 	6.1.7.	Nuokang Medicines Co., Ltd. shall not provide any loan or credit line to anyone without prior written consent from the Pledgee; 

  

	 	6.1.8.	Nuokang Medicines shall operate all business in such a way that its asset value can be maintained, and it shall not be engaged in any action or no-action that adversely
affects its operation and asset value; 

  
  

	 	6.1.9.	In order to protect the titles of Nuokang Medicines’s all assets, the Pledgor shall sign all necessary or appropriate documents, take all necessary or appropriate
actions and advance all necessary or appropriate allegations, or make necessary or appropriate plea for all claims; 

  

	 	6.1.10.	During the term of the Pledge, Nuokang Medicines shall not distribute dividends to its shareholders without prior written consent from the Pledgee;

  

	 	6.1.11.	The Pledgor shall comply with and act according to all laws and regulations relating to the pledge, and present to the Pledgee any notices, orders or suggestions issued
or made by the competent authority in relation to the Pledge within five days upon receiving such notices, orders or suggestions. It shall also comply with such notices, orders or suggestions, or file objection to the foregoing matters at the
reasonable request of the Pledgee or with consent from the Pledgee; 

  

	 	6.1.12.	The Pledgor shall timely notify the Pledgee of (i) any events or any received notices which may affect the Pledgor’s Equity Interest or any part of its right;
and (ii) any events or any received notices which may change any of the Pledgor’s covenants and obligations under this Agreement or which may affect the Pledgor’s performance of its obligations under this Agreement;

  

	 	6.1.13.	The Pledgor acknowledges that, if the Pledgee’s exercise of the Pledge under this Agreement affects the Pledgor’s right to claim for compensation from Nuokang
Medicines, it will expressly waive such rights; 

  

	 	6.1.14.	The Pledgor shall seek the Pledgee’s opinion before appointing directors to Nuokang Medicines in accordance with the articles of association. It shall officially
appoint such directors with prior written consent from the Pledgee; 

  

	 	6.1.15.	The Pledgor agrees and covenants that the Pledgee is entitled to entrust an accounting firm to conduct scheduled or unscheduled audit or investigation on Nuokang
Medicines. It shall unconditionally take actions according to the suggestions related to business management and internal control provided by the accountants after the audit and investigation. 

  
  

	 	6.2.	The Pledgor agrees that the Pledgee’s right to exercise the Pledge acquired under this Agreement shall not be terminated or undermined by legal proceedings
initiated by the Pledgor, its successor or its authorized persons. 

  

	 	6.3.	The Pledgor covenants to the Pledgee that, in order to protect or perfect the security over the payment of the technology consulting service fees under the Service
Agreement, the Pledgor shall execute in good faith and cause other parties who have interests in the Pledge to execute all the title certificates, contracts, and/or perform and cause other parties who have interests to take action as required by the
Pledgee and/or facilitate the exercise of rights and authorization acquired by the Pledgee under this Agreement. It shall also execute, with the Pledgee or the person (natural person or legal entity) designated by the Pledgee, all the documents
relating to a change of the ownership of Equity Interest, and provides all the notices, orders and decisions deemed necessary by the Pledgee to the Pledgee within a reasonable period of time. 

  

	 	6.4.	The Pledgor covenants to the Pledgee that the Pledgor will comply with and perform all the guarantees, covenants, agreements, representations and conditions for the
benefits of the Pledgee. If the Pledgor does not perform or does not fully perform its guarantees, covenants, agreements, representations and conditions, it shall compensate all the damages suffered by the Pledgee. 

  

	7.	Events of Default 

  

	 	7.1.	The following events shall be regarded as the event of default: 

  

	 	7.1.1.	Nuokang Medicines Co., Ltd. fails to make a full payment of the technology consulting service fees as scheduled under the Service Agreement; 

 

	 	7.1.2.	The Pledgor and/or Nuokang Medicines fail to perform obligations under the Operation Agreement and cause damages to the Pledgee; 

  

	 	7.1.3.	The Pledgor makes any fundamentally misleading or fraudulent representations or warranties under Article 5 herein, and/or the Pledgor breaches any warranties under
Article 5 herein; 

  

	 	7.1.4.	The Pledgor violates the covenants under Article 6 herein; 

  
  

	 	7.1.5.	The Pledgor forgoes the Equity Interest under the Pledge or transfers or assigns the Equity Interest under the Pledge without prior written consent of the Pledgee,
except as provided in Article 6.1.1 in this Agreement; 

  

	 	7.1.6.	Any of the Pledgor’s external loan, security, compensation, covenants or any other compensation liabilities (1) are required to be repaid or performed prior
to the scheduled date because of a breach of contract; or (2) are due but cannot be repaid or performed as scheduled, to the extent that the Pledgee deems that the Pledgor’s capacity to perform the obligations herein is affected;

  

	 	7.1.7.	The property of the Pledgor is so adversely changed that it causes the Pledgee to deem that the capacity of the Pledgor to perform the obligations herein is affected;

  

	 	7.1.8.	The successor or administrator of the Pledgor can only partly perform or refuse to perform the payment obligation under the Service Agreement; 

 

	 	7.1.9.	Other circumstances whereby the Pledgee is incapable of exercising its right to dispose of the Pledge in accordance with the related laws. 

  

	 	7.2.	The Pledgor shall immediately give a written notice to the Pledgee if the Pledgor is aware of or finds that any events under Article 7.1 herein or any events that may
result in the foregoing events have happened. 

  

	 	7.3.	Unless the event of default under Article 7.1 herein has been resolved to the Pledgee’s satisfaction, the Pledgee, at any time when the event of default happens or
thereafter, may give a written notice of default to the Pledgor to (i) require the Pledgor to immediately make full payment of the outstanding service fees under the Service Agreement and other payables; or (ii) dispose of the Pledge in
accordance with Article 8 herein. 

  

	8.	Exercise of the Right of the Pledge 

  

	 	8.1.	During the effective term of this Agreement, the Pledgor shall not transfer or assign the Equity Interest without the prior written consent of the Pledgee.

  
  

	 	8.2.	The Pledgee shall give a notice of default to the Pledgor when the Pledgee exercises the right of pledge. 

  

	 	8.3.	Subject to Article 7.3, the Pledgee may exercise the right to dispose of the Pledge at any time when the Pledgee gives a notice of default in accordance with Article
7.3 or thereafter. 

  

	 	8.4.	To the extent laws permit, the Pledgee is entitled to have the priority in receiving proceeds from the auction or sale of whole or part of the Equity Interest pledged
herein in accordance with the legal procedure until the outstanding technology consulting service fees and all other payables under the Service Agreement and the Operation Agreement are fully repaid. 

  

	 	8.5.	The Pledgor shall not hinder the Pledgee from disposing of the Pledge in accordance with this Agreement and shall unconditionally provide necessary assistance upon
Pledgee’s request so that the Pledgee could realize its Pledge. 

  

	9.	Assignment 

  

	 	9.1.	The Pledgor shall not give away or assign his rights and obligations herein without prior consent from the Pledgee. 

  

	 	9.2.	This Agreement shall be binding upon the Pledgor and his successors and shall be binding on the Pledgee and each of its assignees. 

  

	 	9.3.	The Pledgee may transfer all or any of its rights and obligations under the Service Agreement to any individual (natural person or legal entity) it may designate at any
time. In this case, the assignee shall enjoy and undertake the same rights and obligations as the Pledgee hereto as if the assignee is a party hereto. When the Pledgee assigns the rights and obligations under the Service Agreement, at the request of
the Pledgee, the Pledgor shall execute the relevant agreements and/or documents with respect to such assignment. 

  

	 	9.4.	After the identity of the Pledgeee has been changed after the assignment, the new parties to the pledge shall re-execute a pledge contract. 

  

	10.	Termination 

 This Agreement
shall not be terminated until the technology consulting service fees under the Service Agreement are paid off and Nuokang Medicines ceases to bear any obligations under the Service Agreement and the Operation Agreement. The Pledgee shall then cancel
or terminate this Agreement within a reasonable time as soon as practicable. 

  
  

	11.	Processing Fees and other Expenses 

  

	 	11.1.	The Pledgor shall be responsible for all the fees and actual expenses in relation to this Agreement, including but not limited to legal fees, cost of production, stamp
duty and any other taxes and charges. If the Pledgee pays the relevant taxes in accordance with the laws, the Pledgor shall fully reimburse the Pledgee for such tax payments. 

  

	 	11.2.	If the Pledgor fails to pay any payable taxes, fees or charges in accordance with this Agreement or the Pledgee, for certain reasons, has to use other recourses or
means to settle any foregoing taxes, charges or fees by any means, the Pledgor shall be responsible for all the fees (including but not limited to any taxes, processing fees, management fees, litigation expenses, attorney’s fees, and various
insurance premiums) incurred by the Pledgor. 

  

	12.	Force Majeure 

  

	 	12.1.	Force majeure, which includes without limitation acts of governments, acts of nature, fire, explosion, geographical change, typhoon, flood, earthquake, tide, lightning
or war that are inevitable even after the affected party has paid reasonable attention, and such events are beyond the scope that the affected party can reasonably control. However, any shortage of credit, capital or financing shall not be regarded
as an event that beyond any party’s reasonable control. The party which is affected by force majeure and seeks exemption from any obligations under this Agreement or under any article herein shall notify the other party of such exemption
promptly and advise the other party of the steps it needs to take in order to perform this Agreement or the relevant article. 

  

	 	12.2.	When any performance under this Agreement is delayed or prevented by force majeure, provided that the party affected by force majeure has taken its reasonable and
practicable efforts to perform this Agreement, the affected party is exempt from such obligations, the exemption of obligations in favor of the affected party shall be limited to the performance of obligations delayed or prevented by force majeure.
Once causes for such exemptions are rectified and remedied, both parties agree to resume performance of this Agreement with their best efforts. 

  
  

	13.	Dispute Resolution 

  

	 	13.1.	This Agreement shall be governed by and construed in accordance with the PRC law. 

  

	 	13.2.	The parties shall settle any dispute arising from the interpretation or performance, or in connection with this Agreement through friendly consultation. In case no
settlement can be reached through consultation, each party can submit such dispute to China International Economic and Trade Arbitration Commission (“CIETAC”) for arbitration. The arbitration shall follow the currently effective rules of
CIETAC and the arbitration proceedings shall be conducted in Chinese and shall take place in Beijing. The arbitration award shall be final and binding upon the parties. 

  

	14.	Notice 

  

	 	14.1.	Any notice which is given by the parties hereto for the purpose of performing the rights, duties and obligations hereunder shall be in writing. Where such notice is
delivered in person, the time of delivery is the time when such notice actually reaches the addressee; where such notice is transmitted by telex or facsimile, the time of delivery is the time when such notice is transmitted. If such notice does not
reach the addressee on business day or reaches the addressee after the business hour, the next business day following such day is the time of delivery. The delivery address is the address first written above of the parties hereto or the address
advised in writing from time to time. Writing form includes facsimile and telex. 

  

	15.	Effectiveness 

  

	 	15.1.	This agreement and any amendments, modification, supplements, additions or changes hereto shall be in writing and come into effect upon execution and seal by the
parties hereto. 

  

	 	15.2.	This Agreement is written in Chinese and has two counterparts. 

  
 Equity Pledge Agreement 
 (No text on this page) 
 The Pledgee: Penglai Nuokang Pharmaceutical Co., Ltd. (with company seal) 
  

			
	Authorized Representative: /s/ XUE Baizhong
	
	The Pledgor: XUE Baizhong
	
	Signature: /s/ XUE Baizhong

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00165-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00165-of-00352.parquet"}]]